Netherlands Cancer Institute-ko ikertzaileekin lankidetzan egindako argitalpenak (22)

2024

  1. Sotorasib in KRASG12C mutated lung cancer – Authors' reply

    The Lancet

2023

  1. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial

    The Lancet Respiratory Medicine, Vol. 11, Núm. 1, pp. 74-86

  2. Efficacy of T-Cell Receptor-Based Adoptive Cell Therapy in Cutaneous Melanoma: A Meta-Analysis

    Oncologist, Vol. 28, Núm. 6, pp. E406-E415

  3. Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

    Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212

  4. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRASG12C mutation: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 401, Núm. 10378, pp. 733-746

  5. Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 41, Núm. 16, pp. 2893-2903

  6. Tepotinib in patients with non-small cell lung cancer with high-level MET amplification detected by liquid biopsy: VISION Cohort B

    Cell Reports Medicine, Vol. 4, Núm. 11

2022

  1. First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial

    Journal of Thoracic Oncology, Vol. 17, Núm. 2, pp. 289-308

  2. Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

    JTO Clinical and Research Reports, Vol. 3, Núm. 9

  3. Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer

    ESMO Open, Vol. 7, Núm. 2

  4. Trastuzumab deruxtecan in HER2-mutant non–small-cell lung cancer

    New England Journal of Medicine, Vol. 386, Núm. 3, pp. 241-251

2020

  1. Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts

    Radiotherapy and Oncology, Vol. 149, pp. 84-88

2019

  1. Combined PIK3CA and FGFR inhibition with alpelisib and infigratinib in patients with PIK3CA-mutant solid tumors, with or without fgfr alterations

    JCO Precision Oncology

  2. Definition of Synchronous Oligometastatic Non–Small Cell Lung Cancer—A Consensus Report

    Journal of Thoracic Oncology, Vol. 14, Núm. 12, pp. 2109-2119

  3. Prophylactic cranial irradiation in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO experts

    Radiotherapy and Oncology, Vol. 133, pp. 163-166

2018

  1. 30 Immunotherapy in advanced NSCLC-from the ' tsunami' of therapeutic knowledge to a clinical practice algorithm: Results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT)

    ESMO Open, Vol. 3, Núm. 4

  2. Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology

    Clinical Lung Cancer, Vol. 19, Núm. 4, pp. 301-314

2016

  1. Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy

    ESMO Open, Vol. 1, Núm. 6

2015

  1. Monotherapy Administration of Sorafenib in Patients with Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens

    Journal of Thoracic Oncology, Vol. 10, Núm. 12, pp. 1745-1753

2014

  1. Phase I expansion and pharmacodynamic study of the oral MEK inhibitor RO4987655 (CH4987655) in selected patients with advanced cancer with RAS-RAF mutations

    Clinical Cancer Research, Vol. 20, Núm. 16, pp. 4251-4261